ArticleNature metabolism2023
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy.
Open access · hybridAbstract read
In one paragraph
Article in Nature metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 49 citations in OpenAlex.
- MITF-Driven melanoma plasticity as a core mechanism of therapy resistance: integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming.Cell cycle (Georgetown, Tex.) · 2026Review
- NGFR induces melanoma invasion and immunotherapy resistance through myosin light chain 2 modulation.The EMBO journal · 2026Article
- Fatty Acid Metabolism in Health and Cancer: From Fundamental Mechanisms to Therapeutic Application.MedComm · 2026Review
- Radiolabeled Coordination Polymer-Loaded Microneedles for Synergistic Melanoma Brachytherapy-Immunotherapy via STING Activation and Pyroptosis.Exploration (Beijing, China) · 2026Article
- Amino Acids as Targets for Immunotherapy against Solid Tumors.Cell biochemistry and biophysics · 2026Review
- Integrative transcriptomics defines CD36 as a key regulator of immunometabolic signaling in acute myeloid leukemia.Genes & genomics · 2026Article
- Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma.Cell death & disease · 2026Article
- The vaginal microbiome in pregnancy and preterm birth: mechanisms, disparities, and therapeutic opportunities.NPJ biofilms and microbiomes · 2026Review
- BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Molecular biomedicine · 2026Review
- Ferroptosis, pyroptosis, and necroptosis in melanoma: regulatory cell death pathways and their implications for immunotherapy.Frontiers in oncology · 2026Review
- Metabolic adaptations in cancer progression.Physiological reviews · 2026Review
- Role of elevation of glycolysis in tumor-associated macrophages in glioblastoma immune evasion and therapeutic implications.PNAS nexus · 2026Review
- A methyl-to-acetyl switch in H3K27 drives metabolic reprogramming and resistance to BRAFNeoplasia (New York, N.Y.) · 2025Article
- Review
- Untargeted Diversity-Oriented Synthesis for the Discovery of New Antitumor Agents: An Integrated Approach of Inverse Virtual Screening, Bioinformatics, and Omics for Target Deconvolution.Journal of medicinal chemistry · 2025Article
- ERCC1/NGFR affects prognosis in basal-like breast cancer.European journal of medical research · 2025Article
- Metabolic reprogramming in melanoma therapy.Cell death discovery · 2025Review
- Emerging roles for fatty acid oxidation in cancer.Genes & diseases · 2025Review
- The role and mechanism of fatty acid oxidation in cancer drug resistance.Cell death discovery · 2025Review
- Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 10 institutions in 2 countries.
Marta Redondo-Muñoz *Cancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
Francisco Javier Rodriguez-Baena *Instituto de Neurociencias, CSIC-UMH, Sant Joan d'Alacant, Spain.ORCID http://orcid.org/0000-0003-3903-9554
Paula AldazCancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
Adriá Caballé-MestresInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0002-2388-4713
Verónica Moncho-AmorCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.
Maddalen Otaegi-UgartemendiaCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.ORCID http://orcid.org/0000-0002-6600-0463
Estefania Carrasco-GarciaCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.ORCID http://orcid.org/0000-0002-5153-0197
Ana Olias-ArjonaCancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
Irene Lasheras-OteroCancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
Eva SantamariaHepatology Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.ORCID http://orcid.org/0000-0003-0629-6175
Ana BocanegraHealth Research Institute of Navarre (IdiSNA), Pamplona, Spain.ORCID http://orcid.org/0000-0002-3508-0595
Luisa ChocarroHealth Research Institute of Navarre (IdiSNA), Pamplona, Spain.ORCID http://orcid.org/0000-0001-7384-9847
Abby GrierDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID http://orcid.org/0000-0002-5199-8670
Monika Dzieciatkowska MDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID http://orcid.org/0000-0002-9947-2520
Claudia BigasInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Josefina MartinInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0003-2935-9749
Uxue Urdiroz-UrricelquiInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Florencio MarzoHealth Research Institute of Navarre (IdiSNA), Pamplona, Spain.
Enrique SantamariaHealth Research Institute of Navarre (IdiSNA), Pamplona, Spain.
Grazyna KochanHealth Research Institute of Navarre (IdiSNA), Pamplona, Spain.
David EscorsHealth Research Institute of Navarre (IdiSNA), Pamplona, Spain.
Ignacio Marcos LarrayozBiomarkers and Molecular Signaling Group, Center for Biomedical Research of La Rioja (CIBIR), Foundation Rioja Salud, Logroño, Spain.
Holger HeynCNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0002-3276-1889
Angelo D'AlessandroOncoimmunology Group, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.
Camille Stephan-Otto AttoliniInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0001-8045-320X
Ander MatheuCellular Oncology Group, Biodonostia Health Research Institute, San Sebastian, Spain.
Claudia WellbrockCancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain.ORCID http://orcid.org/0000-0002-3825-6381
Salvador Aznar BenitahInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. salvador.aznar-benitah@irbbarcelona.org.ORCID http://orcid.org/0000-0002-9059-5049
Berta Sanchez-LaordenInstituto de Neurociencias, CSIC-UMH, Sant Joan d'Alacant, Spain. berta.lopez@umh.es.ORCID http://orcid.org/0000-0002-6499-6332
Imanol ArozarenaCancer Signaling Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Pamplona, Spain. iarozarm@navarra.es.ORCID http://orcid.org/0000-0001-6349-2442
Universidad Publica de Navarra · ESInstitute for Research in Biomedicine · ESBiogipuzkoa Health Research Institute · ESInstituto de Neurociencias · ESNavarre Institute of Health Research · ESUniversity of Colorado Anschutz Medical Campus · USCentre for Genomic Regulation · ESIkerbasque · ESInstitució Catalana de Recerca i Estudis Avançats · ESUniversidad de La Rioja · ES
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MNCI NIH HHS P30 CA046934
Abstract
Resistance of melanoma to targeted therapy and immunotherapy is linked to metabolic rewiring. Here, we show that increased fatty acid oxidation (FAO) during prolonged BRAF inhibitor (BRAFi) treatment contributes to acquired therapy resistance in mice. Targeting FAO using the US Food and Drug Administration-approved and European Medicines Agency-approved anti-anginal drug ranolazine (RANO) delays tumour recurrence with acquired BRAFi resistance. Single-cell RNA-sequencing analysis reveals that RANO diminishes the abundance of the therapy-resistant NGFR
Indexed as
MelanomaAnimalsImmunotherapyMethionineMiceProtein Kinase InhibitorsRanolazineUnited StatesMethionineProtein Kinase InhibitorsRanolazine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.